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Refinement of survival prediction in patients
undergoing lower extremity bypass surgery:
Stratification by chronic kidney disease
classification
Christopher D. Owens, MD,a Karen J. Ho, MD,a Sang Kim, BS,a Andres Schanzer, MD,a
Julie Lin, MD, MPH,b Evan Matros, MD,a Michael Belkin, MD,a and Michael S. Conte, MD,a
Boston, Mass
Objective: End-stage renal disease (ESRD) imparts a significant survival disadvantage to individuals undergoing lower
extremity revascularization; however, the influence of lesser degrees of renal impairment remains unclear. This study
examined the prognostic significance of the chronic kidney disease (CKD) classification on survival, limb salvage, and
graft patency in patients undergoing lower extremity arterial reconstruction.
Methods:Aprospective registry was evaluated for consecutive patients between January 31, 1995, andDecember 21, 2004,
undergoing first-time, lower extremity vein bypass surgery. Glomerular filtration rate (GFR) was estimated with the
Modification of Diet in Renal Disease equation using each patient’s preoperative creatinine concentration. CKD
categories were taken from current National Kidney Foundation Kidney Disease Outcomes Quality Initiative staging
criteria.
Results: The cohort included 456 subjects, with a mean ( SD) age of 68.1 10.8 years. There were 274 men (60%) and
378 Caucasians (82.5%). Comorbidities included diabetes mellitus in 270 (59.0%), hypertension in 333 (72.7%),
coronary artery disease in 242 (52.8%), and dyslipidemia in 203 (44.5%). The surgical indication was critical limb
ischemia in 384 (83.8%). Among the variables examined, diabetes and critical ischemia as the indication for bypass were
significantly skewed toward higher CKD classifications (P < .001). The 5-year survival rates by CKD class were, CKD
1 and 2, 57%; CKD 3, 46%; CKD 4, 23%; and CKD 5, 9.5%. On univariate analysis, age, coronary artery disease, diabetes
mellitus, hypertension, critical ischemia, and CKD were significant predictors of mortality. After adjustment, however,
only age (hazard ratio [HR], 1.05, 95% confidence interval [CI], 1.03 to 1.06) and CKD stages 4 (HR, 4.23; 95% CI,
2.04 to 8.75) and 5 (HR, 3.27; 95% CI, 1.96 to 5.45) retained significance. Subjects within the CKD 5 classification were
more likely to have a major amputation (P  .018) compared with all other CKD classes. Notably, no relationship was
detected between CKD category and graft patency.
Conclusion: CKD staging adequately differentiates survival curves and risk for major amputation among patients with
renal impairment who are undergoing lower extremity bypass surgery. This may help in clinical decision analysis as well
as in the refinement of stratification in future clinical trial design where survival is an end point. ( J Vasc Surg 2007;45:
944-52.)Cardiovascular disease is the leading cause of morbidity
and mortality among individuals with both chronic
renal insufficiency (CRI)1-4 and peripheral vascular disease
(PAD).5 Nearly 1.2 million individuals with renal insuffi-
ciency also have PAD, indicating a remarkably high 24%
coprevalence of these disorders and making this population
particularly vulnerable to cardiovascular events.6 For pa-
tients with the most severe presentations of PAD—
disabling claudication, rest pain, o r tissue loss—infrainguinal
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944bypass grafting with autogenous vein offers the most dura-
ble and effective revascularization procedure.
In current practices, patients presenting with indica-
tions for infrainguinal bypass are characterized by increas-
ingly complex medical histories and comorbidities. Specif-
ically, among individuals undergoing lower extremity
reconstructions at our institution, the prevalence of chronic
renal insufficiency, defined as preoperative creatinine con-
centration 2 mg/dL, quadrupled from 5% to 21% be-
tween the time intervals 1988 to 1992 and 1993 to 1997.7
The prevalent population on dialysis in the recently com-
pleted multi-institutional, randomized, controlled Edifoli-
gide for the Prevention of Infrainguinal Vein Graft Failure
Trial (PREVENT III) versus placebo in 1400 patients
undergoing lower extremity bypass for critical limb isch-
emia was 12%.8
The vascular surgery literature is replete with single-
institution case series or case–control studies weighing the
merits of revascularization in patients with CRI determined
by abnormal creatinine level,9,10 or patients with end-stage
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alone is an inadequate estimate of kidney function, how-
ever, requiring eGFR to decline to approximately half the
normal level (60 mL/[min · 1.73 m2]) before reaching the
upper limit of normal (Fig 1, A). Further, examining only
those with ESRD fails to account for any biologic gradient
arising from decreasing renal function and the particular
outcome being examined. None of these studies have
therefore been able to determine a threshold of kidney
function in which adverse outcomes increase.
To standardize and simplify recognition, classification,
and treatment of chronic kidney disease (CKD), the Na-
tional Kidney Foundation’s (NKF) Kidney Disease Out-
comes Quality Initiative (KDOQI) recently established
guidelines for defining severity of CKD according to glo-
merular filtration rate (GFR) and the presence of kidney
damage.21,22 Equations for estimating GFR offer a rapid
method of assessing renal function in patients with kidney
disease and are being reported in many clinical laboratories
(Fig 1, B). Common features of these equations are the
reliance on serum creatinine level and demographic and
anthropometric data.
The most commonly used formula was the Cockcroft-
Fig 1. A, Scatter plot shows the distribution of preoperative
serum creatinine concentration within each stage of chronic kidney
disease (CKD) based on kidney function as determined by the
estimated glomerular filtration rate (eGFR), with each point rep-
resenting a single patient and distribution of eGFR. B, Compari-
son of Cockroft-Gault equations and Modified Diet in Renal
Disease formula (MDRD) for eGFR. Age, years; weight, kg; and
serum creatinine, mg/dL. Estimated GFR is calculated by the
MDRD formula.Gault, introduced in 1976,23 on the basis of observations inpredominantly hospitalized patients. The Modified Diet in
Renal Disease (MDRD) equation takes into account serum
creatinine concentration, age, gender, and race and has
been advocated as more accurate and precise than the
Cockcroft-Gault equation at estimating GFR in CKD. It is
validated in African Americans with hypertension, outpa-
tients with moderate-to-advanced kidney disease, and in
those with diabetic nephropathy.24,25
The purpose of this study was to use graded refine-
ments in the classification of kidney function to characterize
the relationship between kidney function and outcomes
(survival, limb salvage, and graft patency) in patients under-
going lower extremity revascularization with autogenous
vein. We also sought to determine if a continuous gradient
of risk or a threshold effect could be demonstrated to relate
renal dysfunction to adverse outcome.
METHODS
Patient selection. We conducted a retrospective re-
view of patients who had undergone primary lower extrem-
ity revascularization using single-segment, autogenous,
great saphenous vein at the Brigham and Women’s Hospi-
tal between January 31, 1995, and December 21, 2004.
Data were retrieved from a UNIX-based computerized
registry (Sun Microsystems, Mountain View, Calif) in
which demographics, risk factors, procedure variables, and
follow-up information have been prospectively entered for
all vascular surgery patients at our institution since 1975.
Patients were excluded if they were undergoing emer-
gency surgery for acute embolic disease or had evidence of
acute renal failure. We limited the study to primary recon-
structions consisting of single-segment great saphenous
vein conduits, thereby excluding the potential confounding
of reoperative procedures or alternative conduits such as
arm veins or spliced grafts.
Routine follow-up consisted of postoperative visits at
1 month and then at 3-month intervals for 1 year, then at
yearly intervals. Duplex surveillance was the primary
method of detecting occult graft lesions. A focal increase in
graft velocity (ratio 3.5:1) and decreased graft velocity
(40 cm/s) were considered significant and were followed
by arteriography and revision when appropriate.
Limb salvagewas defined as freedom frommajor (trans-
tibial or above) amputation. Primary and secondary patency
were defined according the suggested revised reporting
standards of the Society of Vascular Surgeons/Interna-
tional Society for Cardiovascular Surgery ad hoc commit-
tee.26 Death was determined from the electronic medical
record, family member notification, or the Social Security
Death Index.
Assessment of kidney function. All patients in the
study underwent a fasting serum creatinine measurement
on the morning of surgery. Creatinine measurements were
analyzed by a single clinical laboratory (certified by the Clinical
Laboratory Improvement Amendments) of the Brigham
and Women’s Hospital. Creatinine levels were assayed us-
ing the modified Jaffe reaction on anOlympus 2700 instru-
ment (Olympus, Tokyo, Japan) that has a detection limit of
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mg/dL. Because kidney function varies by factors other
than the serum creatinine, we estimated the glomerular
filtration rate (eGFR) using the four-variable, abbreviated
MDRD equation [186  serum creatinine–1.154  age in
years–0.203  1.210 (if African American)  0.742 (if
female)].25
Classification of kidney function. For our initial as-
sessment, classification of kidney function was accom-
plished by categorizing eGFR in mL/[min · 1.73 m2] into
five broad categories: 90, CKD 1 (referent); 60 to 89,
CKD 2; 30 to 59, CKD 3; 15 to 29, CKD 4; and 15 or
hemodialysis dependency, CKD 5. These cut points were
chosen because they correspond to the stages defined by
the NKF KDOQI and are commonly used in research.21
We then modeled eGFR as a continuous variable to deter-
mine the incremental contribution of declining kidney
function. Our final method of analysis dichotomized the
eGFR to above and below 30 mL/(min · 1.73 m2), based
on our observations of similar risk among the CKD 1, 2,
and 3 classifications.
Statistical analysis. Clinical characteristics of study
subjects, stratified according to CKD classification, were
compared using 2 tests for categoric variables and one-way
analysis of variance for continuous variables. The survival,
limb salvage, and primary and secondary patency rates were
calculated by the life-table method. Cox proportional haz-
ard models were used to determine the association between
CKD categories and time-dependant end points, adjusting
for available clinical risk factors.
Similar models were constructed using eGFR as a
continuous variable and, finally, dichotomizing eGFR
above and below 30 mL/(min · 1.73 m2). To test
whether a linear or curvilinear model best described
associations of eGFR (down to 15 mL/[min · 1.73 m2])
and outcomes, a quadratic term was introduced into the
equation. The linear model fit the relationship best and
was consistent with previous reports.1 Multivariable lo-
gistic regression was used to determine associations be-
tween categoric dependant variables and possible inde-
pendent risk factors.
The end points examined were 30-day major adverse
events, 5-year mortality, limb salvage, amputation-free sur-
vival, and 1-year and 5-year primary and secondary graft
patency. Covariates for the multivariable model were se-
lected by examining their statistical significance in univari-
ate analysis or including those covariates that changed the
hazard rate for either eGFR or CKD class by 10% when
placed into a two-variable proportional hazard model.
The final multivariable model included the effects of
age, race, and the presence of coronary artery disease,
diabetes, and hypertension, and critical limb ischemia as the
indication for bypass. Because age and race are incorpo-
rated into the eGFR equation, the inclusion of these vari-
ables in the multivariable models estimates the residual
effects of these variables on the outcomes.
Survival time was calculated from the date of surgery to
the date on which the data were censored or an end pointoccurred. Statistical analysis was performed on Intercooled
STATA 7 software (StataCorp, College Station, Tex).
RESULTS
Baseline characteristics. Our study population con-
sisted of 456 subjects undergoing lower extremity arterial
reconstruction with single-segment, great saphenous vein
between January 1995 and December 2004. The mean
follow-up period was 69.2  28.5 months (median,
69.1months). All patients were followed up for at least
1 year, and 272 were followed up for at least 5 years.
The mean serum 1.27  .30 creatinine concentration
and eGFR in this population was mg/dL and 67.7  29.9
mL/(min · 1.73 m2), respectively, and 51% of the 233
patients had renal insufficiency defined as having an eGFR
60 mL/(min · 1.73 m2), of which 71 (30.5%) were on
hemodialysis. The eGFR values in mL/(min · 1.73 m2)
were 90 in 69 subjects (15.1%), CKD 1; 60 to 89 in 154
(33.8%), CKD2; 30 to 59 in 129 (28.3%), CKD3; 15 to 29
in 32 (7.2%), CKD 4; and 15 in 72 (15.7%), CKD 5. Of
note, one subject in the CKD 5 category was not yet on
dialysis. As expected, subjects with higher CKD classifica-
tions had progressively higher levels of serum creatinine
(P  .0001; Fig 1).
Baseline demographic data across the CKD groups are
summarized in Table I. Subjects with lower eGFR (higher
CKD classification) had significantly higher proportions of
diabetes mellitus, coronary artery disease, and hyperten-
sion. They were alsomore likely to be African American and
have critical limb ischemia as their indication for lower
extremity revascularization. The indication for bypass in
this population was claudication in 72 (15.8%), rest pain in
101 (22.2%), ulceration in 184 (40.4%), and gangrene
in 99 (21.7%; Fig 2, A). Indeed, subjects with increasingly
higher CKD categories were more likely to present with
significant tissue loss such as gangrene; whereas, those
within lower CKD categories were more likely to present
with claudication or rest pain (P  .001; Fig 2, A). Simi-
larly, there was a significant trend for more distal arterial
reconstructions with increasingly higher CKD classifica-
tions (P  .0001; Fig 2, B).
Estimated glomerular filtration rate, renal
impairment, and outcomes
Perioperative (30-day) events. Eight patients died
perioperatively for a 30-day mortality of 1.75%. There were
no perioperative deaths in CKD categories 1 or 2; four in
CKD 3 (3.1%), one in CKD 4 (3.1%), and three in CKD 5
(4.2%; P  NS). There were 31 (6.8%) postoperative
myocardial infarctions (MI): 3 (4.4%) in the CKD 1 cate-
gory, 5 (3.3%) in CKD 2, 8 (6.2%) in CKD 3, 6 (18.2%) in
CKD 4, and 9 (12.7%) in CKD 5. An increased incidence of
postoperative MI was associated with a previous history of
coronary artery disease (adjusted odds ratio [OR], 4.65;
95% confidence interval [CI], 1.68 to 12.80; P  .003),
and having a CKD classification of 4 or 5 (OR, 2.82; 95%
CI, 1.26 to 6.31; P .012). The risk of a postoperative MI
or dying was significantly higher in 17 (16.4%) of 104
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of 350 with eGFR 30 mL/(min · 1.73 m2) (OR, 2.72;
95% CI, 1.27 to 5.83; P .010). There were 25 early graft
failures (30 days of revascularization): 7 in the CKD 1
category, 10 in CKD 2, 5 in CKD 3, 2 in CKD 4, and 1 in
CKD 5. No relationship existed between CKD classifica-
tion and early graft failure. There were 26 (5.7%) wound
complications in this study: 0 in CKD 1 category, 5 (3.3%)
in CKD 2, 13 (10.1%) in CKD 3, 8 (9.1%) in CKD 4, and
Fig 2. A, Indication for lower extremity bypass and B, site of
distal anastomosis by chronic kidney disease (CKD) stage, ex-
pressed as a percentage of total patients. Pop, Popliteal artery;
tibial, anterior or posterior tibial artery or peroneal artery; pedal,
pedal or plantar artery.
Table I. Baseline clinical characteristics* of 456 patients u
stage
Estimated glomer
CKD 1/2* CKD
Characteristic† 60 30-
Patients (n) 223 12
Age, years 67.4  10.6 71.3 
Male gender (%) 139 (62.3) 78 (6
Black 32 (14.4) 13 (1
Diabetes mellitus 104 (46.7) 81 (6
Hypertension 143 (64.1) 99 (7
CAD 98 (44.0) 77 (5
Hyperlipidemia 99 (44.4) 61 (4
Critical ischemia 173 (77.6) 109 (8
Statin use 95 (42.6) 54 (4
ACE inhibitor/ARB use 101 (45.3) 69 (5
CKD,Chronic kidney disease;HD, hemodialysis;HTN, hypertension;CAD
receptor blocker.
*Patients in CKD stages 1 and 2 have been combined.
†Results expressed as n (%) or mean  standard deviation.5 (7.0%) in CKD 5.Mortality. Overall 5-year survival in this cohort of
patients was 43%  3%. When eGFR was modeled as a
continuous variable, the adjusted hazard ratio (HR) was
1.01 (CI, 1.004 to 1.017) for each decrease of 1 mL/
(min · 1.73 m2) in eGFR (P  .001). For each standard
deviation decrease in eGFR (29.9 mL/[min · 1.73 m2]),
the adjusted HR was 1.39 (CI, 1.14 to 1.68; P  .001).
When eGFR was grouped according to CKD classification,
the unadjusted 5-year survival estimates and standard errors
were CKD 1, 57% 7%; CKD 2, 57% 5%; CKD 3, 46% 
5%; CKD 4, 23% 9%; and CKD 5, 9% 4% (P  .0001;
log-rank test; Fig 3, A; Table II).
The unadjusted and multivariable adjusted hazard ra-
tios by CKD classification for mortality are presented in
Fig 4, A. The HR for CKD 2 was equivalent to the referent,
CKD 1. The significant unadjusted HR of CKD 3 for
mortality was attenuated after adjusting for covariates;
however, subjects in both CKD 4 and 5 retained highly
significant hazard ratios even after multivariable adjusting
(P  .0001). Because of similarities in the hazard ratios of
CKD classes 1, 2, and 3 in this population, we constructed
a final model dichotomizing eGFR above or below 30
mL/(min · 1.732) (Table II). The 5-year survival for eGFR
30mL/(min · 1.73 m2) (CKD 1, 2, or 3) compared with
eGFR30 mL/(min · 1.73 m2) (CKD stages 4 or 5), was
53%  4% vs 11%  4% (P  .0001; Fig 3, B).
Limb salvage. The overall 5-year limb salvage rate was
86%  2%. There were 46 amputations: 6 (8.7%) in the
CKD 1 category, 13 (8.4%) in CKD 2, 8 (6.2%) in CKD 3,
3 (9.1%) in CKD 4, and 16 (22.5%) in CKD 5 (P  .014).
Twelve amputations were performed in patients with func-
tioning grafts. Eight of these were in the CKD 5 category,
two were in the CKD 3, and one each in CKD 1 and 2. The
5-year freedom from amputation per CKD category was
89% 5% for CKD 1, 91% 3%, for CKD 2, 93% 3% for
going lower extremity bypass by chronic kidney disease
ltration rate: mL/(min · 1.73 m2)
CKD 4 CKD 5
15-29 15 or HD P
32 72
67.5  11.5 64.6  11.0 .075
19 (59.4) 38 (52.8) .56
8 (25) 27 (37.5) .001
25 (78.1) 60 (83.3) .001
28 (87.5) 62 (86.1) .001
23 (71.9) 44 (61.1) .001
12 (37.5) 31 (43.1) .78
30 (93.8) 72 (100) .001
14 (43.8) 26 (36.1) .79
18 (56.3) 30 (41.7) .24
ary artery disease;ACE, angiotensin-converting enzyme;ARB, angiotensinnder
ular fi
3
59
9
10.3
0.5)
0.1)
2.8)
6.7)
9.7)
7.3)
4.5)
1.9)
3.5)
, coronCKD 3, 77%  14% for CKD 4, and 50%  12% for CKD
survival by (C) CKD classification (D) and eGFR.
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presence of diabetes mellitus, and critical limb ischemia as
the indication for revascularization retained a significant
HR at 2.67 (95% CI, 1.37 to 5.23; P  .004), 2.20 (95%
CI, 1.01 to 4.76; P  .047), and 5.13 (95% CI, 4.23 to
9.81; P  .001), respectively.
Amputation-free survival. For each decrease in eGFR
by 1 mL/(min · 1.73 m2), the adjusted HR was 1.01 (95%
CI, 1.002 to 1.014; P  .006) and for each standard
deviation decrease in eGFR, the HR was 1.28 (95% CI,
1.07 to 1.53; P .006). The unadjusted and multivariable
adjusted HR for each CKD group is considered in Fig 4, B.
The CKD 3 univariate significance was attenuated after
adjustment, leaving only CKD 4 and 5 retaining signifi-
cance for a composite outcome of mortality or amputation,
or both, with HRs of 2.91 (95% CI, 1.48 to 5.76) and 3.19
(95% CI, 1.94 to 5.23), respectively, after full adjustment.
The 5-year amputation-free survival for eGFR 30 mL/
(min · 1.73 m2) (CKD 1, 2, or 3) compared with eGFR
30 mL/(min · 1.732) (CKD 4 or 5), was 49%  3% vs 8
 4% (P  .0001; Fig 3, D).
Graft patency. Overall 5-year primary and secondary
patency for the entire cohort was 56% 3% and 75% 3%,
respectively. Both 1-year and 5-year primary and secondary
graft patency by CKD classification are presented in
Table III. Of importance in this analysis, eGFR did not
influence either primary or secondary graft patency regard-
less of the model. In fact, the only variable examined that
influenced graft patency was African American race, which
significantly negatively impacted secondary patency (HR,
1.82; 95% CI, 1.11 to 3.01; P  .019, Table II).
DISCUSSION
In this study, we used graded refinements in the char-
acterization of kidney function and demonstrated that the
effects of reduced renal function on both survival and
amputation-free survival in patients undergoing lower ex-
tremity revascularization are profound and begin well be-
fore the onset of dialysis. Indeed, the relationship between
reduced renal function and survival appears linear between
an eGFR of 90 and 15 mL/(min · 1.73 m2), so that for
every decrease in eGFR of 30 mL/(min · 1.73 m2), there is
a relative 39% increased likelihood of death. As such, the
presence of severe CKD, particularly an eGFR 30 mL/
(min · 1.73 m2) (CKD 4 and 5), is a powerful independent
prognostic factor for the risk of death and amputation in
this patient population. This same population is also at
significantly increased risk of having a perioperative major
adverse cardiac event (death or MI).
These data are consistent with those from other patient
populations in which eGFR has been used in risk stratifica-
tion.4,27 Hemmelgarn et al,4 in a series of 8521 patients
undergoing cardiac catheterization, noted an increased risk
of death when the eGFR was79 mL/(min · 1.73 m2). In
this large study, they were also able to determine a relative
increase in the risk of mortality by 17.2% for each decline in
eGFR by 10 mL/(min · 1.73 m2), suggesting a dose-Fig 3. Kaplan-Meier estimates of overall survival by (A) chronic
kidney disease (CKD) classification and (B) estimated glomerular
filtration rate (eGFR). Kaplan-Meier estimates of amputation-freeresponse relationship between renal function and survival.
refere
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death at a threshold eGFR of 60 mL/(min · 1.73 m2) in a
large community-dwelling population and in individuals
having presented with an acute coronary syndrome.28,29
It is still unclear if this association between reduced
renal function and survival is causal. Patients with CKD
Table II. Association of estimated glomerular filtration ra
patency
Covariates Amputation
P
Mortality
Adjusted HR* HR (CI) HR (CI)
eGFR† 2.13 (1.01-4.76) .028 4.48 (3.27-6.1
Age (per year) .99 (.96-1.02) .89 1.05 (1.03-1.0
Race (black) 1.86 (.98-3.53) .059 .70 (.49-1.01
Diabetes mellitus 2.20 (1.01-4.76) .047 1.07 (.79-1.45
CAD .86 (.47-1.56) .614 1.28 (.97-1.68
Hypertension 1.50 (.68-3.30) .314 1.19 (.86-1.65
CLI 5.13 (4.23-9.81) .001 1.55 (.96-2.48
HR, Hazard ratio; CI, confidence interval; CLI, critical limb ischemia; CAD
*All hazard ratios shown are fully multivariable adjusted.
†Estimated glomerular filtration rate (eGFR 30 ml/min · 1.73 m2) is the
Fig 4. A, The risk of mortality and the B, combined end point of
death and amputation by chronic kidney disease (CKD) stage after
5 years. Hazard ratios and 95% confidence intervals are shown.
†CKD 1, or GFR 90 mL/(min · 1.73 m2) is the referent. ‡MV,
multivariable.have higher proportions of coronary risk factors, complexmedical histories, and multiple comorbidities.30 Several
studies have documented an increased prevalence of tradi-
tional cardiac risk factors in patients with reduced renal
function.31,32 Yet, conventional risk factors alone cannot
explain the increase mortality risk in this population. Evi-
dence for this stems from the documented discrepancies
between calculated Framingham 10-year risk scores that
underestimate risk compared with actual cardiovascular
event rates.33,34
A number of nontraditional cardiac risk factors have
therefore been implicated to account for this apparent
discrepancy. These include associations with markers of
inflammation, albuminuria, low serum albumin (reflecting
inflammation and malnutrition) anemia, reduced vascular
compliance, homocystinemia, and abnormal oxidation lev-
els.35-38 The association between reduced renal function
and inflammation is intriguing. Large prospective case–
control studies such as the Nurses Health Study have found
that there exists an inverse relationship of eGFR and
biomarkers of inflammation such as high-sensitive C-reactive
protein (hsCRP), interleukin 6, and soluble tumor necrosis
factor receptor.35,36 Others have noted that elevated
hsCRP was significantly associated with malnutrition, ane-
mia, and higher hospitalization rate in predialysis pa-
tients.37,38
Whether this relationship simply reflects a decrease in
renal clearance or whether these markers of systemic in-
flammation have an active biomodulating role in the
atherogenic process has not been determined. We have,
however, recently demonstrated that hsCRP independently
predicts the risk of major adverse cardiovascular and graft-
related events in patients undergoing lower extremity by-
pass with vein.39 It is perhaps likely that eGFR offers a
convenient, easily measured surrogate for some of these
nontraditional cardiac risk factors.
Arguments of causality include the strength of the
association (HR 3) of eGFR and decreased survival, the
biologic gradient (dose-response relationship), consistency
of association among diverse populations, verification by
multiple investigators, and perhaps most compelling, the
biologic plausibility. Included in this are considerations of
th amputation, mortality, primary patency, and secondary
P
Primary patency
P
Secondary patency
PHR (CI) HR (CI)
.001 .79 (.46-1.18) .202 1.01 (.58-1.76) .974
.001 1.00 (.98-1.02) .915 .99 (.97-1.01) .270
.055 1.30 (.85-1.99) .222 1.82 (1.11-3.01) .019
.647 1.34 (.94-1.93) .109 1.11 (.68-1.81) .688
.083 .81 (.58-1.14) .228 .80 (.51-1.26) .334
.291 1.23 (.84-1.80) .294 1.51 (.87-2.61) .144
.070 1.06 (.66-1.70) .815 1.75 (.82-3.76) .150
onary artery disease.
nt.te wi
3)
6)
)
)
)
)
)
, corthe atherogenic milieu resulting from the interplay of tra-
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mic patient ultimately leading to impaired endothelial func-
tion40-43 and to adverse clinical outcomes.30
Despite the vascular biology of the renally impaired
patient, no trial to date has been able to determine an
association between renal impairment and vein graft
patency.9-12,15,17,19,44 Indeed, many authors have postu-
lated that this lack of association is related to the high
mortality rate in these patients and that they may be dying
with patent grafts.12 According to the United States Renal
Data System (USRDS) 2005 morbidity and mortality re-
port, only 34% of individuals who begin dialysis will be alive
in 5 years.45 By contrast, our patients who are undergoing
lower extremity revascularization and are arguably sicker
than the community-dwelling individual initiating hemo-
dialysis have 5-year life expectancy of only 9%. Any exami-
nation of patencymust therefore be tempered by the dismal
survival in patients who are severely renally impaired or who
are receiving renal replacement therapy.
Nevertheless, our 1-year primary and secondary pa-
tency rates compare favorably with many published re-
ports.11,12,17 This reflects, in part, that only single-segment
great saphenous veins were included in this analysis and
thereby diminishes confounding from disadvantaged con-
duits. One advantage of classification of renal function
according to CKD category is the determination of incre-
mental association of renal impairment with graft patency.
On examination of the first 4 columns of Table III, it
becomes obvious that no such relationship exists.
This best-vein-case scenario, however, should also offer
the most optimal limb salvage rates in patients at CKD 5.
Although our 1-year limb salvage rate is 82%, the 5-year
rate is only 50%. This is particularly disturbing because
open bypass grafts were present in eight of the 16 amputa-
tions in patients with CKD 5. This underscores the fact that
surgical patients on dialysis behave significantly differently
than other classifications of CKD. Factors such as malnu-
trition, poor wound healing, susceptibility to infection, low
systolic blood pressure, and blood pressure fluctuations
during dialysis may confound our ability to determine who
is at risk for amputation.
Some limitations to this study merit consideration. The
MDRD and the Cockcroft-Gault equations have both been
Table III. One-year and five-year outcomes of primary an
kidney disease stage
CKD stage
Primary patency Secondary pa
1-year 5-year 1-year
CKD 1 71  6 56  6 86  4
CKD 2 70  4 59  5 81  3
CKD 3 71  4 51  6 88  3
CKD 4 77  8 60  16 88  6
CKD 5 70  6 63  7 80  5
CKD, Chronic kidney disease.
Results expressed as mean  standard error.reported to be less accurate in populations without kidneydisease.46,47 This was largely the result of the equations
being developed and validated in populations with CKD
rather than in healthy, community-dwelling individuals.
The biologic and measurement variability may also be
greater at higher GFR levels.46
Because this was a retrospective study, we do not have
information on how eGFR changes over time. As such, we
have not quantified the rate of decline of the renal function,
which may be as important as the absolute value of renal
function itself.
There are likely unaccounted confounders such as the
level of systemic inflammation, time on dialysis, extent and
distribution of ulceration or gangrene, quality of the vein,
quality of the runoff, and vessel calcification. Other unac-
counted for variables may include biochemical abnormali-
ties associated with azotemia such as low albumin, anemia,
intact parathyroid hormone levels, and the calcium–
phosphate ion product. Ideally, these factors would be
noted in a prospective evaluation.
Further, because this cohort only included single-
segment vascular grafts and therefore excluded high-risk
alternative conduits such as spliced arm vein, it is arguably
biased toward the best-case scenario for bypass outcome.
Finally, the retrospective nature of the report precludes us
from commenting on what factors were considered in
selecting these patients for vascular reconstructive surgery
rather than offering them primary amputation, hence intro-
ducing a patient selection bias.
CONCLUSIONS
We believe eGFR, as predicted by the MDRD equa-
tion, is a more accurate reflection of renal function. It is
noteworthy that although a progressive decline in eGFR
does impart a survival disadvantage, no such relationship
exists in outcomes related to the vein graft. It is significant
that only half of the patients in CKD 4 and 5 categories
were receiving statin therapy, emphasizing that this popu-
lation is undertreated and that evidence-based practice
guidelines are needed.
Clearly, the overall burden of renal insufficiency and its
attendant comorbidities in patients undergoing lower ex-
tremity revascularization are substantial and significantly
affect long-term survival and limb salvage. Continual vigi-
ondary patency, limb salvage and survival by chronic
Limb salvage Survival
r 1-year 5-year 1-year 5-year
5 92  3 89  5 95  3 57  8
4 93  2 91  3 90  2 57  5
4 95  2 93  3 84  3 46  5
16 92  5 77  15 60  9 23  9
10 82  5 50  12 54  6 9  4d sec
tency
5-yea
80 
74 
80 
57 
61 lance and determination of modifiable traditional and non-
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Volume 45, Number 5 Owens et al 951traditional cardiovascular risk factors that contribute to
these poor outcomes are incumbent to those involved in
treating these challenging patients.
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preparation.
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